Our subgroup analyses according to hospitalization status during the acute phase of the infection show that the salutary association of SGLT2 inhibitors with both MACE and MAKE was weaker among those hospitalized than non-hospitalized – which may explain the results of these two trials. The gene discussed is SLC5A2; the disease is infection.